High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 355-358

  De Felice, Catia ^a,b   Mazzotta, Annamaria ^a   Esposito, Maria ^a   Bianchi, Luca ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE   (Italy)

Author keywords

Etanercept; Psoriatic arthritis; Tumour necrosis factor alpha

Indexed keywords

ETANERCEPT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERAL CONDITION IMPROVEMENT; HERPES; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; INSTRUMENT; LABORATORY TEST; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SAMPLE SIZE; SIDE EFFECT; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; AGED; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 34250182036     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028703     Document Type: Article

References (15)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20.
2. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868-72.
3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-96.
4. Krueger GG, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
5. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol. 1998;38:479-85.
6. Spadaro A, Taccari E, Mohtadi B, Riccieri V, Sensi F, Zoppini A. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: Comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol. 1997;15:609-14.
7. Ortonne J-P. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140:1-7.
8. Gaspari A, Gottlieb AB, Kang S. Etanercept improves the clinical and pathological features of psoriasis. Presented at the Society for Investigative Dermatology, 2002.
9. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2269-72.
10. Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol. 2005;152:187-9.
11. Mease P, Goffe B, Metz J, Vanderstoep A. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet. 2000;356:385-90.
12. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:401-8.
13. Lebwohl MG, Gottlieb AB, Wallis WJ, Zitnik RJ. Global safety and efficacy of more than five years of etanercept (Enbrel) therapy in rheumatoid arthritis. Presented at the American Academy of Dermatology 62nd Annual Meeting; Washington, DC, 2004: poster P550.
14. Greaves MW, Weinstein GD. Drug therapy: Treatment of psoriasis. N Engl J Med. 1995;332:581-8.
15. De Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26-week observational study. Rheumatology (Oxford). 2006;45:321-4. Epub 2005 Oct 18.